Csenge Advisory Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Csenge Advisory Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$405K	Buy	+3,168	New	+$395K	0.02%	485
2024 Q4	–	Sell	-10,623	Closed	-$1.05M	–	769
2024 Q3	$1.05M	Buy	+10,623	New	+$1.04M	0.05%	259
2024 Q2	–	Sell	-2,186	Closed	-$207K	–	761
2024 Q1	$207K	Buy	+2,186	New	+$203K	0.01%	669
2022 Q2	–	Sell	-10,463	Closed	-$940K	–	690
2022 Q1	$940K	Buy	+10,463	New	+$966K	0.07%	232
2019 Q2	–	Sell	-19,247	Closed	-$1.74M	–	221
2019 Q1	$1.74M	Sell	19,247 -257	-1%	-$21.9K	0.6%	31
2018 Q4	$1.4M	Buy	19,504 +2,486	+15%	+$200K	0.51%	40
2018 Q3	$1.27M	Buy	17,018 +329	+2%	+$31.9K	0.5%	41
2018 Q2	$1.59M	Buy	16,689 +399	+2%	+$36.7K	0.58%	41
2018 Q1	$1.43M	Sell	16,290 -854	-5%	-$78K	0.5%	49
2017 Q4	$1.46M	Sell	17,144 -1,738	-9%	-$146K	0.52%	48
2017 Q3	$1.63M	Buy	+18,882	New	+$1.51M	0.65%	33

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Csenge Advisory Group's XBI Position: Q1 2026 in Review

Csenge Advisory Group opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 3,168 shares worth $405K. The stake represents 0.02% of the portfolio and ranks #485 among its holdings. This is a return to the name: Csenge Advisory Group previously reported a position in XBI as recently as Q3 2024.

Csenge Advisory Group first reported a position in XBI in Q3 2017 and has held it in 11 quarters since. The position peaked at $1.74M in Q1 2019. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Csenge Advisory Group held 3,168 shares of State Street SPDR S&P Biotech ETF worth $405K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new Csenge Advisory Group position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.02% of Csenge Advisory Group's portfolio in Q1 2026, its #485 holding.
Csenge Advisory Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and has held it in 11 quarters since.
Csenge Advisory Group's State Street SPDR S&P Biotech ETF position peaked at $1.74M in Q1 2019.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Csenge Advisory Group's 13F filing for Q1 2026, filed 30 Apr 2026.